- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 27 July 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a marketing authorisation for the medicinal product Valdoxan/Thymanax, 25 mg film-coated tablets intended for the treatment of major depressive disorder. The company that applied is Les Laboratoires Servier. The applicant requested a reexamination of the opinion, but withdrew this request before the CHMP completed the re-examination.
Product details
- Name of medicine
- Thymanax
- Active substance
- Agomelatine
- International non-proprietary name (INN) or common name
- agomelatine
- Therapeutic area (MeSH)
- Depressive Disorder, Major
Assessment history
This page was last updated on